Abstract
Background: Oral Lichen Planus (OLP) is one of the most common oral mucosal diseases. However, the current diagnostic method for OLP has limitations, and sometimes it is easy to be misdiagnosed. Salivary metabolomics may provide new ideas for the diagnosis of OLP.
Objective: To identify the biomarkers for the early detection of OLP.
Methods: A non-targeted metabolomic analysis method was established based on UHPLC-Q-Orbitrap HRMS (Ultra-performance liquid chromatography-quadrupole/orbitrap high resolution mass spectrometry) to analyze the differential metabolites in saliva samples of patients with OLP and healthy subjects. Saliva samples were collected from 120 OLP patients and 125 healthy subjects.
Results: A total of 19 differential metabolites were identified, including 6 amino acid metabolites, 2 carnitines, 2 lipid metabolites and 9 other metabolites. The integrated biomarkers were constructed by 3 metabolites according to Receiver Operating Characteristic (ROC). Meanwhile, multiple metabolic pathways were found to be involved in the occurrence and development of OLP.
Conclusion: Metabolomics can be used to characterize the characteristics of metabolic disorders in patients with OLP, which is also helpful to the early diagnosis of OLP and reveal the pathological process of OLP.
Keywords: Oral lichen planus, UHPLC-Q-orbitrap HRMS, metabolomics, precancerous lesion, biomarkers, saliva.
Recent Patents on Anti-Cancer Drug Discovery
Title:Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification
Volume: 16 Issue: 3
Author(s): Xiaoshuang Wang, Liwei Liu, Qiuzheng Du, Zhi Sun, Erli Yue, Peng Xue*Hongyu Zhao*
Affiliation:
- Health Management Centre, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,China
- Stomatological Hospital of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,China
Keywords: Oral lichen planus, UHPLC-Q-orbitrap HRMS, metabolomics, precancerous lesion, biomarkers, saliva.
Abstract:
Background: Oral Lichen Planus (OLP) is one of the most common oral mucosal diseases. However, the current diagnostic method for OLP has limitations, and sometimes it is easy to be misdiagnosed. Salivary metabolomics may provide new ideas for the diagnosis of OLP.
Objective: To identify the biomarkers for the early detection of OLP.
Methods: A non-targeted metabolomic analysis method was established based on UHPLC-Q-Orbitrap HRMS (Ultra-performance liquid chromatography-quadrupole/orbitrap high resolution mass spectrometry) to analyze the differential metabolites in saliva samples of patients with OLP and healthy subjects. Saliva samples were collected from 120 OLP patients and 125 healthy subjects.
Results: A total of 19 differential metabolites were identified, including 6 amino acid metabolites, 2 carnitines, 2 lipid metabolites and 9 other metabolites. The integrated biomarkers were constructed by 3 metabolites according to Receiver Operating Characteristic (ROC). Meanwhile, multiple metabolic pathways were found to be involved in the occurrence and development of OLP.
Conclusion: Metabolomics can be used to characterize the characteristics of metabolic disorders in patients with OLP, which is also helpful to the early diagnosis of OLP and reveal the pathological process of OLP.
Export Options
About this article
Cite this article as:
Wang Xiaoshuang , Liu Liwei, Du Qiuzheng , Sun Zhi , Yue Erli , Xue Peng *, Zhao Hongyu *, Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification, Recent Patents on Anti-Cancer Drug Discovery 2021; 16 (3) . https://dx.doi.org/10.2174/1574892816666210224160120
DOI https://dx.doi.org/10.2174/1574892816666210224160120 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Recognition of Lung Adenocarcinoma-specific Gene Pairs Based on Genetic Algorithm and Establishment of a Deep Learning Prediction Model
Combinatorial Chemistry & High Throughput Screening Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets Current Challenges and Future of Lipid Nanoparticles Formulations for Topical Drug Application to Oral Mucosa, Skin, and Eye
Current Pharmaceutical Design Withdrawal Notice: The Prognostic Value of Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma in Iranian Population
Current Cancer Therapy Reviews Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia
CNS & Neurological Disorders - Drug Targets Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets Modulation of MMP-9 Pathway by Lycopene in Macrophages and Fibroblasts Exposed to Cigarette Smoke
Inflammation & Allergy - Drug Targets (Discontinued) The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry